Onset and Duration of Adverse Events in Patients Treated With Fenfluramine in the Lennox-Gastaut Syndrome Clinical Trials

Introduction

- Lennox-Gastaut syndrome (LGS) is a developmental and epileptic encephalopathy characterized by drug resistant seizures of multiple types^{1,2}
- There are a range of anti-seizure medications (ASMs) available that vary in mechanism of action, efficacy, and safety and tolerability³
- Since a patient-focused approach involves a balance of ASM safety and efficacy, understanding adverse event (AE) characteristics is important for providers, patients and families³
- Fenfluramine (FFA) is currently approved for the management of seizures associated with LGS in the US in patients ≥ 2 years old,⁴ and as add-on treatment for patients ≥ 2 years old with seizures associated with LGS in the EU, UK, Japan, and Israel⁵⁻⁸
- The FFA LGS clinical trial program involves a phase 3 trial of two parts: a randomized controlled trial (RCT)⁹ and open-label extension (OLE)¹⁰ (NCT03355209)

Objective

• This post-hoc analysis describes the time of onset and duration of treatment-emergent adverse events (TEAEs) reported in the FFA RCT and OLE

Methods

- In the RCT, patients with LGS (aged 2-35 years) enrolled from study sites in North America, Europe, and Australia were randomized to FFA 0.2 mg/kg/day or FFA 0.7 mg/kg/day (maximum 26 mg/day) or placebo
- After 2 weeks titration and 12 weeks maintenance in the RCT, patients could enroll in the OLE part where they were transitioned to FFA 0.2 mg/kg/day for 1 month, then were flexibly titrated to effect and tolerability \geq Month 2 (see overview in **Figure 1**)
 - Changes in concomitant ASMs were not permitted during the RCT
 - In the OLE, patients must have remained on a stable ASM regimen, including ≥ 1 concomitant ASM, for the first 6 months of the study; decreases in doses or discontinuation of ASMs were allowed after Month 6 but treatment with ≥ 1 concomitant ASM was required

Figure 1. FFA LGS RCT and OLE Study Overview



FFA, fenfluramine; LGS, Lennox-Gastaut syndrome; OLE, open-label extension; RCT, randomized controlled trial.

• For this post-hoc analysis, the following were reported:

- Incidence of TEAEs occurring in $\geq 10\%$ of patients in the RCT and OLE (previously reported,^{9,10} reviewed in **Table 1**) by week of first onset of first occurrences
- In the RCT, median time to onset and duration of first occurrences of TEAEs occurring in $\geq 10\%$ of patients were reported by dose groups
- Median time to onset of first occurrences of TEAEs occurring in $\geq 10\%$ of patients in the OLE (any dose) and percent of patients who experienced resolution of those TEAEs were reported

Table 1. Overview of TEAEs Occurring in $\geq 10\%$ of Patients per Treatment Group in the RCT and Any Dose in the OLE

FFA Study	Treatment Group	Patients Experiencing ≥1 TEAE, n (%)	Patients Experiencing TEAEs Occurring in ≥10% of Patients, n (%)	TEAEs Occurring in ≥10% of Patients			
LGS RCT ^{9,11}	Placebo (n=87)	65 (74.7)	35 (40.2)	Decreased appetite (11.5%), pyrexia (11.5%), somnolence (10.3%), fatigue (10.3%)			
	FFA 0.2 mg/kg/day (n=89)	69 (77.5)	42 (47.2)	Decreased appetite (20.2%), vomiting (13.5%), diarrhea (11.2%), pyrexia (10.1%), somnolence (10.1%)			
	FFA 0.7 mg/kg/day (n=87)	78 (89.7)	52 (59.8)	Decreased appetite (35.6%), fatigue (18.4%), somnolence (17.2%), diarrhea (12.6%)			
LGS OLE ¹⁰	Any dose (N=247)	203 (82.2)	127 (51.4)	Decreased appetite (16.2%), fatigue (13.4%), nasopharyngitis (12.6%), seizure (10.9%)			

FFA, fenfluramine; LGS, Lennox-Gastaut syndrome; OLE, open-label extension; RCT, randomized controlled trial; TEAE, treatment-emergent adverse

Definitions:

- Time to onset is measured from the first date of FFA initiation in either RCT or OLE
- Duration of the event is based on the number of days from AE onset date to resolution date
- Descriptive statistics were used

(?) QUESTION

Q

RESULTS


 TEAEs reported in ≥10% of patients per randomized treatment group of the RCT, median time to onset, and proportion of patients experiencing resolution of first occurrences of those TEAEs are reported in the **Table** • In the OLE, TEAEs reported in $\geq 10\%$ of patients included: decreased appetite (16.2%), fatigue (13.4%), nasopharyngitis (12.6%), and seizure (10.9%); percent of patients experiencing resolution of first occurrences are described in the **Figure**



Results

• Incidence of TEAEs occurring in $\geq 10\%$ of patients by week of first onset of <u>first occurrences</u> in the RCT and in the OLE are described in Figure 2A and Figure 2B, respectively

Figure 2. Pooled Incidence of TEAEs Occurring in ≥10% of Patients by Week of First Onset of First Occurrences A. In the RCT (N=263)^{a,b} **B.** By Flexible Dose in the OLE (N=247)^c



^aTEAEs occurring in \geq 10% of patients in either treatment group were: decreased appetite, somnolence, fatigue, pyrexia, diarrhea, and vomiting. ^bTwo patients experienced TEAEs on the last day of FFA treatment in the RCT, a few days beyond 14 weeks (98 days), which accounts for TEAEs listed at Week 15. ℃TEAEs occurring in ≥10% of patients were: decreased appetite, fatigue, nasopharyngitis, and seizure; there were no first occurrences of these after Week 57. FFA, fenfluramine; OLE, open-label extension; PBO, placebo; RCT, randomized controlled trial; TEAEs, treatment-emergent adverse events.

Overview

What data are available related to the onset and duration of treatmentemergent adverse events (TEAEs) reported in the clinical trials of fenfluramine (FFA) in patients with Lennox-Gastaut syndrome (LGS)?



NVESTIGATION

The safety and effectiveness of FFA were evaluated in previously published studies, specifically a 14-week randomized-controlled trial (RCT) and subsequent open-label extension (OLE) study (NCT03355209). This post-hoc analysis of those studies describes the time of onset and duration of TEAEs occurring in $\geq 10\%$ of patients in those studies.

Table. Median Time to Onset and Proportion of Patients Experiencing Resolution of First Occurrences of TEAEs Occurring in \geq 10% of Patients in the FFA RCT

5						
	Placebo	FFA 0.2 mg/kg/day	FFA 0.7 mg/kg/day			
	n=87	n=89	n=87			
Diarrhea, n (%)	NA	10 (11.2)	11 (12.6)			
Median time to onset, days (range)		9.5 (2-86)	16 (2-86)			
% of patients with resolution		90.0%	90.9%			
Vomiting, n (%) Median time to onset, days (range) % of patients with resolution	NA	12 (13.5) 14 (1-101) 100%	NA			
Fatigue, n (%)	9 (10.3)	NA	16 (18.4)			
Median time to onset, days (range)	4 (1-99)		6.5 (1-41)			
% of patients with resolution	66.7%		56.3%			
Pyrexia, n (%)	10 (11.5)	9 (10.1)	NA			
Median time to onset, days (range)	28.5 (2-92)	20 (5-92)				
% of patients with resolution	100%	100%				
Decreased appetite, n (%)	10 (11.5)	18 (20.2)	31 (35.6)			
Median time to onset, days (range)	10 (1-85)	10 (1-69)	11 (1-91)			
% of patients with resolution	80.0%	72.2%	45.2%			
Somnolence, n (%)	9 (10.3)	9 (10.1)	15 (17.2)			
Median time to onset, days (range)	14 (1-96)	17 (1-75)	6 (1-95)			
% of patients with resolution	55.6%	77.8%	80.0%			

adverse events.

First occurrences of TEAEs are reported early in FFA treatment and are associated with high percentages of resolution. FFA continues to be a well-tolerated treatment option for patients with LGS.

- 45.2%-100% of patients


Dose Group

		Diarrhea		Vomiting		Fatigue		Pyrexia		Decreased Appetite		Somnolence	
		Onset	Duration	Onset	Duration	Onset	Duration	Onset	Duration	Onset	Duration	Onset	Duration
Placebo n=87	n Median, days (range)	NA	NA	NA	NA	9 4 (1-99)	6 20.5 (3-71)	10 28.5 (2-92)	10 2.5 (1-6)	10 10 (1-85)	8 28 (8-65)	9 14 (1-96)	5 37 (4-42)
FFA 0.2 mg/kg/day n=89	n Median, days (range)	10 9.5 (2-86)	9 2 (1-60)ª	12 14 (1-101)	12 1.5 (1-54)ª	NA	NA	9 20 (5-92)	9 3 (1-10)	18 10 (1-69)	13 15 (4-98)	9 17 (1-75)	7 18 (1-42)
FFA 0.7 mg/kg/day n=87	n Median, days (range)	11 16 (2-86)	10 5 (1-32)	NA	NA	16 6.5 (1-41)	9 51 (4-101)	NA	NA	31 11 (1-91)	14 25.5 (4-97)	15 6 (1-95)	12 14.5 (4-75)

^aThe maximum end of the range was due to one patient. adverse events.

Joseph Sullivan, MD¹, Lieven Lagae, MD, PhD, FRCP², Raman Sankar, MD, PhD³, Kelly G. Knupp, MD⁴, Sameer M. Zuberi, MD⁵, Antonio Gil-Nagel, MD, PhD⁶, Ingrid E. Scheffer, MBBS, PhD, FRACP, FRS⁷, Renzo Guerrini, MD, FRCP⁸, Adam Strzelczyk, MD, MHBA, FEAN⁹, Kate Riney, MB BCh BAO, PhD¹⁰, Patrick Healy¹¹, Jayne Abraham, PhD¹¹, Mélanie Langlois, PhD¹², Amélie Lothe, PhD¹², Rima Nabbout, MD, PhD¹³

¹University of California San Francisco Weill Institute for Neurosciences, Benioff Children's Hospital, San Francisco, CA. USA: ²Member of the European Reference Network EpiCARE, University of Leuven, Leuven, Belgium; ³David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA; ⁴University of Colorado, Children's Hospital Colorado, Aurora, CO, USA; ⁵Paediatric Neurosciences Research Group, Royal Hospital for Children, Glasgow, UK: ⁶Hospital Ruber Internacional, Madrid, Spain: ⁷University of Melbourne, Austin Hospital and Royal Children's Hospital, Florey and Murdoch Children's Research Institutes, Melbourne, Victoria, Australia ³Meyer Children's Hospital IRCCS, and University of Florence, Florence, Italy; ⁹Goethe-University Frankfurt, Frankfurt am Main, Germany; ¹⁰The University of Queensland, St Lucia, QLD, 4067, Australia, Queensland Children's Hospital, South Brisbane, QLD, 4101, Australia; ¹¹UCB, Smyrna, GA, USA; ¹²UCB, Colombes, France; ¹³Member of the European Reference Network EpiCARE, Reference Centre for Rare Epilepsies, Necker Enfants Malades Hospital, APHP, U 1163 Institut Imagine, Université Paris Cité, Paris, France



• **Table 2** describes median time to onset and duration of first occurrences of TEAEs occurring in $\geq 10\%$ of patients in the RCT • Decreased appetite and somnolence occurred in $\geq 10\%$ of patients in all RCT groups (placebo and FFA)

• Of the FFA treatment groups, earliest median time to onset of TEAEs occurred in patients treated with FFA 0.7 mg/kg/day who experienced somnolence (n=15; median, 6 days; range, 1-95) and fatigue (n=16; median, 6.5 days; range 1-41) • First occurrence of pyrexia and vomiting resolved in all patients

• Vomiting resolved in 12/12 patients on FFA 0.2 mg/kg/day within a median duration of 1.5 days (range, 1-54)

• Pyrexia resolved in 10/10 patients in the placebo group within a median of 2.5 days (range, 1-6) and in 9/9 patients treated with FFA 0.2 mg/kg/day within a median of 3 days (range, 1-10)

• Of the patients randomized to an FFA treatment group who experienced a TEAE occurring in $\geq 10\%$ of patients, resolution occurred in

Table 2. Median Time to Onset and Duration of First Occurrences of TEAEs Occurring in $\geq 10\%$ of Patients in the FFA RCT by

FFA, fenfluramine; LGS, Lennox-Gastaut syndrome; NA, not applicable, since the TEAE occurred in <10% of patients in that group; OLE, open-label extension; RCT, randomized controlled trial; TEAEs, treatment-emergent

- (75.8%)
- (81.5%)

Conclusions

References

11. Data on file, UCB; 2024

Acknowledgements

Disclosures

JS: Research grants: Stoke, Marinus, Zogenix (now a part of UCB), Biopharm; Consultant/Advisor: Dravet Syndrome Foundation, Epygenix, Encoded, GW Pharma (now Jazz Pharmaceuticals), Asceneuron, Longboard Pharmaceuticals, Knopp Biosciences, Neurocrine; Stock options: Epygenix; Travel support: Zogenix (now a part of UCB); Reviewer: Epilepsy Study Consortium. LL: Received grants and is a consultant and/or speaker for Zogenix (now a part of UCB), LivaNova, UCB, Shire, Eisai, Novartis, Takeda/Ovid, NEL, and Epihunter. RS: Received grants or contracts from DoD and NINDS; has received book royalties from Cambridge University Press and Demos; has received consulting fees from Aquestive, Eisai, and UCB; has received payment or honoraria for lectures, presentations, speak-ers bureaus, manuscript writing, or educational events from Aquestive, BioMarin, Jazz Pharmaceuticals, Neurelis, SK Life Science, UCB, and Zogenix (now a part of UCB); and has participated on a Data Safety Monitoring Board for Takeda. KGK: Research grants from Zogenix (now a part of UCB) and Pediatric Epilepsy Research Foundation during the conduct of the study, as well as from the Colorado Department of Public Health and West Therapeutics; received other support as a data safety monitoring board member and from GW Pharma (now Jazz Pharmaceuticals). SMZ: Research support from Epilepsy Research UK, Dravet Syndrome UK, and Zogenix (now a part of UCB), and has served as consultant/speaker and advisory board member for GW Pharma (now Jazz Pharmaceuticals), Encoded Therapeutics, Stoke Therapeutics, Eisai, UCB, Jaguar Gene Therapy, Arvelle, and Zogenix (now a part of UCB). AGN: Served on speakers bureau, advisory boards, or committees for Angelini Pharma, Bial, Biocodex, Eisai, Esteve, GW Pharma (now Jazz Pharmaceuticals), Oils 4 Cure, Pharvaris, PTC Therapeutics, Rapport Therapeutics, Stoke, UCB Pharma, and Zogenix (now a part of UCB Pharma). Has received research support from Biogen, Jazz Pharmaceuticals, PTC Therapeutics, and UCB Pharma. **IES:** Served on scientific advisory boards for BioMarin, Chiesi, Eisai, Encoded Therapeutics, GlaxoSmithKline, Knopp Biosciences, Nutricia, Rogcon, Takeda Pharmaceuticals, UCB, and Xenon Pharmaceuticals; has received speaker honoraria from GlaxoSmithKline, UCB, BioMarin, Biocodex, Chiesi, Liva Nova and Eisai; has received funding for travel from UCB, Biocodex, GlaxoSmithKline, Biomarin and Eisai; has served as an investigator for Anavex Life Sciences, Cerebral Therapeutics, Cereval Therapeutics, Eisai, Encoded Therapeutics, EpiMinder Inc, Epygenyx, ES-Therapeutics, GW Pharma (now Jazz Pharmaceuticals), Marinus, Neurocrine BioSciences, Ovid Therapeutics, Takeda Pharmaceuticals, UCB, Ultragenyx, Xenon Pharmaceutical, Zogenix (now a part of UCB) and Zynerba; and has consulted for Atheneum Partners, Care Beyond Diagnosis, Epilepsy Consortium, Ovid Therapeutics, UCB and Zynerba Pharmaceuticals, Stoke Therapeutics, Praxis; and is a Non-Executive Director of Bellberry Ltd. and a Director of the Australian Academy of Health and Medical Sciences. RG: Research grants from Zogenix (now a part of UCB) during the conduct of the study, served as speaker/consultant for Zogenix (now a part of UCB) outside the submitted work, has served as an investigator for studies with Biocodex, UCB, Angelini, and Eisai, and has served as speaker and advisory board member for Biocodex, Novartis, BioMarin, and GW Pharma (now Jazz Pharmaceuticals). AS: Received personal fees and grants from Angelini Pharma, Biocodex, Desitin Arzneimittel, Eisai, Jazz Pharmaceuticals, Takeda, UCB, and UNEEG medical. KR: Received honoraria for educational symposia, advisory boards, and/or consultancy work from Eisai, LivaNova, MedLink Neurology, Novartis, and UCB Australia. Her institution has supported clinical trials for Biogen Idec Research, DSLP, Eisai, Epigenyx Therapeutics, GW Research, Janssen-Cilag, Longboard Pharmaceuticals, Marinus Pharmaceuticals, Medicure International, LivaNova, Neurocrine Biosciences, Noema Pharma, Novartis, SK Lifesciences, Takeda Pharmaceutical Company Limited, UCB Australia, UCB Biopharma, and Zogenix (now a part of UCB). PH, JA, ML, AL: Employees and Stock Ownership, UCB. RN: Research funding from Eisai, GW Pharma (now Jazz Pharmaceuticals), Novartis, Shire, UCB, and Zogenix Inc (now a part of UCB); consultant/advisor for Eisai, Biogen, GW Pharma (now Jazz Pharmaceuticals), Novartis, Shire, and Zogenix Inc (now a part of UCB); speaker for Advicenne, Eisai, BioMarin, GW Pharma (now Jazz Pharmaceuticals), Novartis, and Zogenix Inc (now a part of UCB).



 In the OLE, median time to TEAE onset and percent of patients experiencing resolution of first occurrences was reported for the following TEAEs:

• **Decreased appetite** (n=40): median time to onset, 51.5 days (range, 1-397); resolution in 29 patients (72.5%)

• **Fatigue** (n=33): median time to onset, 60 days (range, 1-362); resolution in 25 patients

• **Nasopharyngitis** (n=31): median time to onset, 87 days (range, 9-360); resolution in 100% of patients

• **Seizure** (n=27): median time to onset, 92 days (range, 1-267); resolution in 22 patients

• Flexible dosing in the OLE limited analysis of time to resolution

• Late-onset first occurrence of TEAEs could be related to other ASMs introduced or dose increases that took place during the OLE study

These results provide further insight on TEAEs reported by $\geq 10\%$ of patients in the LGS clinical trials. Incidence of first onset of TEAEs was most common during the RCT titration phase and the flexible dose phase in the OLE. Of the first occurrences of TEAEs, a high proportion of patients experienced resolution regardless of FFA dose received in either the RCT or OLE. These data demonstrate that FFA is generally well tolerated, which may contribute to health-related quality of life outcomes in patients with LGS.

- L. Gastaut H, et al. *Epilepsia*. 1966;7(2):139-79.
- 2. Cross JH, et al. *Front Neurol.* 2017;8:505. Strzelczyk A, Schubert-Bast S. CNS Drugs. 2021;35(1):61-83.
- 4. UCB Inc. FINTEPLA[®] (fenfluramine) oral solution [prescribing information]. Smyrna, GA; March 2023.
- 5. UCB. Fintepla 2.2 mg/mL oral solution [summary of product characteristics]. Bruxelles, BE; 2024.
- 6. UCB Pharma LTD. Fintepla 2.2 mg/ml oral solution [summary of product characteristics]. Slough, Berkshire; April 2024.
- 7. UCB Pharma S.A. 2024. https://israeldrugs.health.gov.il/#!/medDetails/169%2041%2036976%2099. 8. Nippon Shinyaku Co. Ltd. 2024. <u>https://www.nippon-shinyaku.co.jp/file/download.php?file_id=7484</u>
- 9. Knupp K, et al. *JAMA Neurol.* 2022;79(6):554-64.
- 10. Knupp KG, et al. *Epilepsia.* 2023;64(1):139-51.

UCB Pharma-sponsored. The authors acknowledge Tom Grant, PhD (UCB Pharma, Slough, UK), for managing the development of the poster, and Sandra M Aguero, PharmD, BCPS, and Scott Bergfeld, PhD, of PharmaWrite, LLC (Princeton, NJ, USA), for writing and editorial assistance, which was funded by UCB Pharma.

- For a copy of this poster, use your smartphone to scan the QR code, download from the website below, or contact UCBCares®
- Website: UCBposters.com/AES2024; Poster ID: AES2024-2.393 Phone: +1-844-599-CARE (2273)
- Email: UCBCares@ucb.com



American Epilepsy Society 78th Annual Meeting Los Angeles, CA, USA | December 6–10, 2024